Tarsus Pharmaceuticals
↗Irvine, California, United States
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for eye care and infectious disease prevention. Founded in 2016 by Bobak Azamian and Michael Ackermann, the company has rapidly established itself as a leader in ophthalmic therapeutics with its first and only FDA-approved treatment for Demodex blepharitis. Tarsus applies proven science and novel technology to address previously unmet patient needs, starting with eye care and expanding into adjacent therapeutic areas. The company's pipeline leverages the well-characterized anti-parasitic agent lotilaner (licensed from Elanco) adapted for multiple indications.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Biopharmaceutical / Ophthalmology
SIZE & FINANCIALS
Employees:201-500
Revenue:$300M-$500M (2025 projected: $440M-$445M)
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Commercial
Total Raised:$60M Series B (2020) + $200M Pharmakon debt financing (2024)
Investors:Vivo Capital, Frazier Healthcare Partners, Flying L Partners, Visionary Ventures, Aperture Venture Partners, Horowitz Group, Pharmakon Advisors (debt financing)
STOCK
Exchange:NASDAQ
Ticker:TARS
Market Cap:$3.4B (as of Q3 2025)
PIPELINE
Stage:Commercial/Phase 2
Lead Drug Stage:FDA Approved
Modalities:Small molecule, Topical ophthalmic solution, Oral tablet
Active Trials:3
Trial Phases:Phase 2: 2
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Elanco Tiergesundheit AG (IP licensing for active ingredient lotilaner), International partners for geographic expansion (China, Japan, Europe)
COMPETITION
Position:Leader (first-to-market for Demodex blepharitis treatment; establishing new disease category)
Competitors:Allergan/AbbVie (Restasis, Botox, comprehensive eye care portfolio), Bausch Health (dermatology and eye care focus), Regeneron Pharmaceuticals (EYLEA for retinal diseases), Novartis (dry eye and ophthalmic franchise), Alcon (general ophthalmology), Akorn Inc. (specialty eye care)
LEADERSHIP
Key Executives:
Bobak Azamian, MD, PhD - President, CEO and Chairman
Michael Ackermann - Co-Founder
Sesha Neervannan - Chief Operating Officer
Leo Greenstein - Chief Financial Officer
Dianne Whitfield - Chief Human Resources Officer
Bryan Wahl - General Counsel
Aziz Mottiwala - Chief Commercial Officer
David Pyott - Board Member
Scientific Founders:Bobak Azamian, MD, PhD
Board Members:Bobak Azamian, MD, PhD (Chairman), David Pyott (Board Member)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Tarsus Pharmaceuticals and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Tarsus Pharmaceuticals. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.